Research directory

Clinical trials

Find trials by company, ticker, title or NCT ID.

Filters
Reset
1,647 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric CataractNCT04539548OCULPhase 3Completed2023-12-21Actual
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NCT04544293SVRAPhase 3Active not recruiting2023-11-30Actual
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHNCT04544410Spruce BiosciencesPhase 2Terminated2024-10-31Actual
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19NCT04551911OPKPhase 2Completed2021-10-08Actual
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389KPTIPhase 3Active not recruiting2026-02-20Actual
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870KPTIPhase 2Active not recruiting2026-09Estimated
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)NCT04568434IONSPhase 3Completed2023-07-14Actual
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)NCT04569435ANNXPhase 2Completed2024-01-10Actual
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaNCT04571645Jazz PharmaceuticalsPhase 3Terminated2022-05-16Actual
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentNCT04576156Geron CorporationPhase 3Active not recruiting2028-06-30Estimated
A Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT04576949Achieve Life SciencesPhase 3Completed2021-12-23Actual
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaNCT04577352PTC TherapeuticsPhase 2, Phase 3Completed2023-04-04Actual
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT04578548LKFTPhase 2Terminated2022-12-14Actual
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomNCT04583995NovavaxPhase 3Completed2022-03-29Actual
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830Polaris GroupPhase 2Active not recruiting2027-02-28Estimated
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersNCT04588428Inovio PharmaceuticalsPhase 2Completed2023-01-19Actual
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)NCT04592419KODPhase 3Completed2022-06-10Actual
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874ALECPhase 2Completed2024-08-19Actual
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerNCT04596150CytomX TherapeuticsPhase 2Completed2023-06-02Actual
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisNCT04598269ACRSPhase 2Completed2021-04-08Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624SUPNPhase 2Completed2021-09-28Actual
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04603937KODPhase 3Terminated2023-04-27Actual
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152KODPhase 3Terminated2023-05-11Actual
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2NCT04611802NovavaxPhase 3Completed2023-04-10Actual
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103IOVAPhase 2Recruiting2030-12Estimated
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionNCT04614467LSTAPhase 2Terminated2022-09-28Actual
Study of Exchange of Travoprost Intraocular ImplantNCT04615403Glaukos CorporationPhase 2Completed2022-02-28Actual
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949CRDLPhase 2, Phase 3Terminated2022-11-30Actual
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924RedHill Biopharma LimitedPhase 3Terminated2023-08-28Actual
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNCT04617054NUVBPhase 2Terminated2024-12-06Actual

Primary completion marks the end of data collection for the main study measures, not a results publication date.